Emergent BioSolutions announced that its COVID-19 Human Immune Globulin (COVID-HIG) product candidate will be evaluated in an NIH-sponsored phase 3 clinical trial of hyperimmune intravenous immunoglobulins to treat COVID-19

GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.

Read More

Neumann University Sisters Offer Prayers From the Porch
Delco Today

Coronavirus has caused most of the Sisters of St. Francis at Neumann University to maintain a healthy social distance from the students there.

Despite this hurdle, Sr. Marguerite O’Beirne, OSF, Neumann’s vice president for mission and ministry, and Sr. Linda DeCero, OSF, director of pastoral ministry, aren’t letting the virus interfere with their roles on campus.

Read More

Brian Tierney is happy to announce Tierney Business Networks will continue where Streamline Payroll left off.

The attached brochure is a golf outing supporting Family Services of Buck County.  This organizations has supported families in need in our area for years. Brian is on the board for the golf committee helping to promote and support this event.  He will be there on October 5th continuing to network, promoting business and charity event similar to this.

Read More

Philadelphia Business Journal

Bentley Systems Inc., an Exton software company founded by a team of five brothers 36 years ago, reached a milestone Wednesday when it debuted on the Nasdaq stock exchange. Shares opened at $22 and shot up more than 52% to close at $33.49.

The company, a maker of leading software applications for engineers who design large infrastructure projects like the new Tappan Zee Bridge in New York —  raised more than $235 million in its IPO under the ticker symbol BSY.

Unlike other IPOs, where a company issues new shares in order to raise cash and fuel expansion, Bentley Systems is only selling shares already owned by its more than 4,000 employees. The idea is to reward those employees with liquidity, CEO Greg Bentley said, after they helped the company get to where it is today.

Click HERE to read more.

Irish drug that could cure Parkinson’s Disease sold for $446 million

Dr. Jeremy Skillington, Vice President of Business Development for Inflazome, travelled to Philadelphia to participate in our Life Sciences Forum this January. In one of the largest deals in Irish biotech history, Inflazome, based out of Trinity, has been sold to Roche.

The Dublin-based drug sells opening treatment of Alzheimer’s, Parkinson’s, and cardiovascular disease to the market.

An Irish company that develops treatments for inflammatory diseases, a collaboration between Trinity College Dublin and the University of Queensland, has been sold for an up-front payment of $446m (€380m) from Roche, plus additional payments based on the achievement of certain milestones.

Read More